Intuitive Surgical Forecasts 13–15% Procedure Growth in 2026, Flags Policy Headwinds
Intuitive Surgical forecasts 13–15% growth in da Vinci procedures for 2026, down from 18% in 2025, driven by rising adoption in U.S. general surgery and international expansion. Management warns of U.S. reimbursement shifts and capital constraints in Europe and Asia that could temper system placements and procedure volumes.
1. 2026 Procedure Growth Guidance
Intuitive Surgical projects 13–15% growth in da Vinci procedures for fiscal 2026, moderating from the nearly 18% expansion achieved in 2025. This guidance underscores management’s confidence in sustaining momentum despite normalization from peak levels.
2. U.S. and International Growth Drivers
In the United States, increased adoption of robotic-assisted general surgeries, expanding indications and enhanced workflow efficiencies support procedure volume. Internationally, growth is propelled by broader market access, targeted training initiatives and deeper penetration across Europe and Asia.
3. Macroeconomic and Policy Headwinds
Management highlighted potential headwinds from U.S. reimbursement dynamics, including changes to ACA subsidies and Medicaid funding that could impact hospital volumes. Outside the U.S., capital constraints in Europe, competitive tender pressures in China and ongoing reimbursement reviews in Japan introduce variability.
4. Revenue Leverage and Valuation Impact
The recurring-revenue model links procedure volumes to instruments and services revenues, providing strong operating leverage even at mid-teens growth. Intuitive Surgical trades at a forward P/E of 44.4, above the industry average but below its five-year median, reflecting premium valuation supported by durable demand.